Wall Street analysts forecast that Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) will report sales of $720,000.00 for the current quarter, Zacks reports. Three analysts have made estimates for Oramed Pharmaceuticals’ earnings, with estimates ranging from $600,000.00 to $850,000.00. Oramed Pharmaceuticals posted sales of $600,000.00 during the same quarter last year, which would indicate a positive year over year growth rate of 20%. The company is scheduled to issue its next earnings report on Monday, April 8th.
According to Zacks, analysts expect that Oramed Pharmaceuticals will report full-year sales of $2.94 million for the current year, with estimates ranging from $2.50 million to $3.56 million. For the next fiscal year, analysts forecast that the firm will report sales of $2.60 million, with estimates ranging from $2.40 million to $2.80 million. Zacks’ sales calculations are an average based on a survey of research firms that cover Oramed Pharmaceuticals.
Get Oramed Pharmaceuticals alerts:Separately, HC Wainwright set a $25.00 price objective on Oramed Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, December 12th.
NASDAQ:ORMP traded down $0.01 during trading hours on Friday, hitting $3.24. The company’s stock had a trading volume of 9,904 shares, compared to its average volume of 37,285. The stock has a market capitalization of $56.49 million, a price-to-earnings ratio of -3.77 and a beta of 0.94. Oramed Pharmaceuticals has a 52-week low of $2.78 and a 52-week high of $8.59.
A hedge fund recently raised its stake in Oramed Pharmaceuticals stock. BlackRock Inc. raised its position in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) by 137.2% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 69,343 shares of the biotechnology company’s stock after purchasing an additional 40,114 shares during the period. BlackRock Inc. owned about 0.40% of Oramed Pharmaceuticals worth $208,000 at the end of the most recent reporting period. 10.24% of the stock is owned by institutional investors.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes.
Recommended Story: What are different types of coverage ratios?
Get a free copy of the Zacks research report on Oramed Pharmaceuticals (ORMP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment